Genetic drugs based on nucleic acid biomolecules are a rapidly emerging class of
medicines that directly reprogramme the central dogma of biology to prevent and treat …

Messenger RNA (mRNA) is an emerging class of therapeutic agent for the prevention and
treatment of a wide range of diseases. The recent success of the two highly efficacious …

Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients, yet harbours
mutation-derived T cell neoantigens that are suitable for vaccines,. Here in a phase I trial of …

Due to the fact that mRNA technology allows the production of diverse vaccines and
treatments in a shorter time frame and with reduced expense compared to conventional …

The extraordinary success of mRNA vaccines against coronavirus disease 2019 (COVID-19)
has renewed interest in mRNA as a means of delivering therapeutic proteins. Early clinical …

The emergency use authorizations (EUAs) of two mRNA-based severe acute respiratory
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …

The approval of the first immune checkpoint inhibitors provided a paradigm shift for the
treatment of malignancies across a broad range of indications. Whereas initially, single …

To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …

RNA-based gene therapy requires therapeutic RNA to function inside target cells without
eliciting unwanted immune responses. RNA can be ferried into cells using non-viral drug …

The oncofetal antigen Claudin 6 (CLDN6) is highly and specifically expressed in many solid
tumors, and could be a promising treatment target. We report dose escalation results from …